Defensin human neutrophil peptide-2 - RELIEF THERAPEUTICS Holding

Drug Profile

Defensin human neutrophil peptide-2 - RELIEF THERAPEUTICS Holding

Alternative Names: Defensin HPN2

Latest Information Update: 12 Oct 2016

Price : $50

At a glance

  • Originator mondoBIOTECH
  • Developer RELIEF THERAPEUTICS Holding
  • Class Peptides
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Vascular disorders

Most Recent Events

  • 16 Sep 2016 Defensin human neutrophil peptide-2 is available for licensing as of 16 Sep 2016. http://www.relieftherapeutics.com/further-opportunities/
  • 18 Jul 2016 THERAMetrics has merged with Relief Therapeutics forming RELIEF THERAPEUTICS Holding
  • 14 May 2014 mondoBIOTECH has patent protection for defensin human neutrophil peptide-2 in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top